Skip to main content

Parsaclisib FDA Approval Status

FDA Approved: No
Generic name: parsaclisib
Company: Incyte
Treatment for: Non-Hodgkin's Lymphoma

Parsaclisib is a next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ) in development for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).

Development timeline for parsaclisib

Jan 25, 2022Incyte Provides Update on Parsaclisib and MCLA-145
Nov  1, 2021Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.